SFB1399: PD Dr. rer. nat. Cécile Gouttefangeas

Academic education

1988 - 1989: Diploma thesis at the INSERM Unit 93, University Paris VII, France. (head of Department: Prof. Dr. L. Degos)
1984 - 1988: Study in Biochemistry, University Paris XI, France

Scientific degrees

2016: Habilitation in immunology, University of Tübingen
1993: PhD thesis at the INSERM Unit 93 (head of Department: Prof. Dr. L. Degos), University Paris VII, France (Identification of new functional populations of human T lymphocytes), (fellowship from the Ministry of Research and Education)

Scientific career

2004 - present: Group leader at the Institute for Cell Biology, Department of Immunology, University of Tübingen, Germany (Adaptive immunity against tumors and T cell monitoring). Teaching duties at the University of Tübingen (since 2008)
2001 - present: Scientific associate at the Institute for Cell Biology, Department of Immunology, University of Tübingen, Germany
1997 - 2001: Post-doctoral position at the Institute for Cell Biology, Department of Immunology (head Prof. H. G. Rammensee), Tübingen, Germany. Fellowship from the European Union (Marie Curie Program, Brussels, Belgium)
1994 - 1996: Post-doctoral position at the INSERM Unit 395 (head Prof. C. de Préval), Toulouse, France (grants from the Association for Cancer Research and the National League Against Cancer).

Honors/ Awards/ Memberships

2015 - present: Member of the Deutsche Gesellschaft für Immunologie (DGfI)
2006 - present: Member of the Association for Cancer Immunotherapy (CIMT)
2005 - present: Founding member and steering committee member (chair person 2012-2013) of the International Monitoring Panel then CIMT Immunoguiding Program (CIP), a working group of the Association for Cancer Immunotherapy (CIMT).

10 most relevant publications

Zelba H, Bedke J, Hennenlotter J, Mostböck, Zettl M, Zichner T, Chandran A, Stenzl A, Rammensee HG, Gouttefangeas C. PD-1 and LAG-3 dominate checkpoint receptor-mediated T cell inhibition in renal cell carcinoma. Cancer Immunol Res 2019 Sep 4. doi: 10.1158/2326-6066.CIR-19-0146 [Epub ahead of print]
Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, …Dietrich PY, Wick W. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 2019, Jan:565:240-245
Dimitrov S*, Gouttefangeas C*, Besedovsky L, Jensene ATR, Chandran PA, Rusch E, Businger R, Schindler M, Lange T, Born J, Rammensee HG*. Activated integrins identify functional antigen-specific CD8+ T cells within minutes after antigen stimulation. Proc Natl Acad Sci USA 2018 Jun;115(24):E5536-E5545. * Corresponding authors.
Löffler MW, Chandran PA, Laske K, Schroeder C, Bonzheim I, Walzer M, Hilke FJ, Trautwein N, Kowalewski DJ, Schuster H, Günder M, Carcamo Yañez VA, Mohr C, Sturm M, Nguyen HP, Riess O, Bauer P, Nahnsen S, Nadalin S, Zieker D, Glatzle J, Thiel K, Schneiderhan-Marra N, Clasen S, Bösmüller H, Fend F, Kohlbacher O, Gouttefangeas C, Stevanović S, Königsrainer A, Rammensee HG. Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient. J Hepatol. 2016 Oct; 65(4):849-55.
Kvistborg P*, Gouttefangeas C*, Aghaeepour N, Cazaly A, Chattopadhyay PK, Chan C, Eckl J, Finak G, Hadrup SR, Maecker HT, Maurer D, Mosmann T, Qiu P, Scheuermann RH, Welters MJP, Ferrari G, Brinkman RR, Britten CM. Thinking outside the gate: single-cell assessments in multiple dimensions. Immunity 2015 Apr; 42(4):591-2. *equal contribution.
Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJM, O’Donnell-Tormey J, Odunsi K, Old LJ, Ottenhoff THM, Ottensmeier C, Pawelec G, Roederer M, Roep BO, Romero P, van der Burg SH, Walter S, Hoos A, Davis MM. T cell assays and MIATA: The essential minimum for maximum impact. Immunity 2012 July; 37(1):1-2.
Widenmeyer M, Griesemann H, Stevanović S, Feyerabend S, Klein R, Attig S, Hennenlotter J, Wernet D, Kuprash DV, Sazykin AY, Pascolo S, Stenzl A, Gouttefangeas C*, Rammensee HG. Promiscuous survivin peptide induces robust CD4(+) T-cell responses in the majority of vaccinated cancer patients. Int J Cancer 2012 July;131(1):140-149 *Corresponding author.
Attig S, Hennenlotter J, Pawelec G, Klein G, Koch S, Pircher H, Feyerabend S, Wernet D, Stenzl A, Rammensee HG, Gouttefangeas C. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res 2009 Nov; 69(21):8412-19.
Britten CM*, Gouttefangeas C*, Schoenmaekers-Welters MJ, Pawelec G, Koch S, Ottensmeier C, Mander A, Walter S, Paschen A, Müller-Berghaus J, Haas I, Mackensen A, Køllgaard T, Thor Straten P, Schmitt M, Giannopoulos K, Maier R, Veelken H, Bertinetti C, Konur A, Huber C, Stevanović S, Wölfel T, van der Burg SH. The CIMT-Monitoring panel: A two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother 2008 March; 57(3):289-302. *equal contribution.
Weinschenk T, Gouttefangeas C, Schirle M, Obermayr F, Walter S, Schoor O, Kurek R, Loeser W, Bichler KH, Wernet D, Stevanovic S, Rammensee HG. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res 2002 Oct; 62(20):5818-27.

Patents

Co-inventor of international patents on HLA-peptides and T-cell epitopes derived of (WO/2009/138236, WO/2011/073215)

CV

PD Dr. rer. nat. Cécile Gouttefangeas